Newport-based Xanodyne Pharmaceuticals Inc. has sold the global rights of women’s health product Lystedal to Ferring Pharmaceuticals, a privately owned specialty biopharmaceutical group headquartered in Switzerland. The sale is part of Xanodyne’s plan to tighten its focus on the pain management market, where it has a decade-long history with brands such as Darvocet and Roxicodone. The most recent addition to the company’s pain portfolio is Zipsor liquid-filled capsules, a non-steroidal anti-inflammatory drug that was approved by the FDA in June 2009. Financial details of the Xanodyne-Ferring transaction have not been disclosed.
Newport
The Lane Report
- General Fund and Road Fund receipts reported for fiscal year 2025
- PSC and KCTCS join forces with new PSC 811 Damage Prevention Scholarship
- Crave Hot Dogs & BBQ launches inside Louisville Walmart
- Crunch Fitness brings state-of-the-art fitness facility to Lexington
- Gov. Beshear announces $14.4 million to improve infrastructure damaged in 2022 floods
- BreyerFest 2025: Cheers to 75 Years of Horse Magic at the Kentucky Horse Park
- 8 Kentucky companies awarded nearly $750,000 to continue technology development in the Commonwealth
- Op-Ed: Proposed Federal cuts hurt KET
- New study reveals which metro areas have the most and least disposable income in Kentucky
- Saint Joseph London pulmonologist performs first robotic-assisted bronchoscopy
Add Comment